Clinical Trial Search

Primary: Change is Leptin to Adiponectin Ratio (LAR) — 2.2; 1.3; 1.3; 1.4 ng/micrograms

Primary: PTH (Parathyroid Hormone) Adherence — 0.23; 0.28 probability of having a PTH measured — p=0.04

Primary: Patient Activation Measure (PAM) -13 Item Questionnaire — 9.1; -1.4 points — p=0.01

Primary: Phosphocreatine (PCR) Recovery Time After Knee Extension Assessed by 31 Phosphorus Magnetic Resonance Spectroscopy (31P-MRS) — 60.59; 62.66 seconds

Primary: Sit to Stand to Sit Speed: Time Taken to Sit to Stand to Sit 10 Times — 23.8; 22.9 seconds

Primary: Mortality — 0; 0 percentage of mortality

Primary: The Patient Activation Measure (PAM) — 60.8; 61.5; 1.73; 3.44 score on a scale

Primary: Change in Urine cAMP Concentration and Urine Osmolality (UOsm) — -2.6; -2.0 fold change in cAMP/UOsm (umol/UOsm)

Primary: Fibroblast Growth Factor 23 (FGF-23) — 162.695; 297; 188.975; 143.7675 RU/ml

Primary: Number of Participants With CKD Diagnosis — 417; 389 Participants — p=.21

Primary: Number of Participants With Treatment-related Adverse Events — 0 Participants

Primary: Qualitative Survey Assessmentof Perceived Usefulness of the Med-alert Device. — 1 Likert scale

Primary: Percent Change From Baseline to Day 169 (Week 24) in UACR - Per Protocol Population — -14.82; -17.25; -31.45; -29.70 Percentage change from baseline — p=0.8338

Primary: Change in Resting Muscle Sympathetic Nerve Activity (MSNA) — -7.5; 3.2 bursts/minute

Primary: Change in Proteinuria — -34; -133 mg/g creatinine — p=0.04

Primary: Effect of Vitamin D Supplementation on Albuminuria in CKD Patients as Assessed by Urine Albumin/Creatinine Measures. — 1126.68; 1061.39 mg/gram creatinine

Primary: Change in Brachial Artery Flow Mediated Dilation (FMD) — 1.1; -0.7 absolute change in percent FMD

Primary: Change in Mean Serum Copeptin From Baseline (a Reflection of Endogenous Vasopressin Production) at Week 2 — -0.86; 0.39 pmole/L — p=<0.01

Primary: Treatment-specific Baseline Estimated Glomerular Filtration Rate Based on Creatinine (eGFRcr) — 32.7; 34.9 mL/min/1.73m^2

Primary: Change From Baseline in Log Transformed Urine Albumin Creatinine Ratio (UACR) Measured in 10-hour Urine After 20 Weeks of Trial Treatment — -0.069; -0.029; -0.217; 0.034…

Primary: Change in Quantitative Computed Tomography (QCT) Bone Mineral Density of the Hip — -10.71; 5.72; -3.52; .2 g/cm^3 — p=.443

Primary: Change in Endothelial Dependent Dilation From Baseline to Week 12 — 0.2; 0.9 % change — p=0.47

Primary: Composite Global Cognitive Function — .15; .02 Z-score

Primary: Change in Baseline and 2 Week FMD/VP Measurements Between Sildenafil Group and Placebo Group — 10.8; 8.6 Change in FMD%

Primary: Change in Urinary Albumin:Creatinine Ratio (ACR) — -52.55555556; 46.44444444 ratio

Primary: Change in Peak Aerobic Capacity — 17.1; 16.8; 17.9; 15.9 ml/kg/min

Primary: the Occurrence of Cardiovascular Event and Peritonitis Events — 0; 0; 0; 0 participants — p=>0.05

Primary: The Discrete Incidence of Any of the Chronic Kidney Disease Patient Safety Indicators (CKD-PSIs) Endorsed by the Consensus Expert Panel — 108.7; 100.6; 38.3; 41.2 events…

Primary: Change in Urinary Albumin Excretion From Baseline to 4 Months — -28.6; -5.6 mg/g — p=0.17

Primary: Categorical Change in Urinary Albumin-to-creatinine Ratio (UACR) From Baseline — 1; 7; 5 Participants